Lyell Immunopharma Inc Ordinary Shares LYEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
-
Lyell Immunopharma Announces Participation in September Investor Conferences
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,727.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 224
- Website
- https://www.lyell.com
Comparables
Valuation
|
Metric
|
LYEL
|
ACLX
|
ARTV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.55 | 8.61 | — |
Price/Sales | 5,727.70 | 27.51 | 4.39 |
Price/Cash Flow | — | 507.02 | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LYEL
|
ACLX
|
ARTV
|
|---|---|---|---|
Quick Ratio | 15.90 | 5.85 | 4.43 |
Current Ratio | 16.19 | 6.01 | 4.59 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
LYEL
ACLX
ARTV
Profitability
|
Metric
|
LYEL
|
ACLX
|
ARTV
|
|---|---|---|---|
Return on Assets (Normalized) | −21.42% | −1.88% | −16.21% |
Return on Equity (Normalized) | −24.51% | −3.31% | — |
Return on Invested Capital (Normalized) | −26.29% | −7.10% | — |
Return on Assets
LYEL
ACLX
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rcmzgpgrc | Ffwf | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xtdnjnwn | Llzfpz | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tgmftgqf | Vbqdvr | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pltjjjkjk | Zbslsf | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Wmrkzxzp | Gzd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Gkvsrfjy | Hxgdy | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lkvxkqgqd | Sdmwj | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xsxfnxpmg | Nylf | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hkdvtyw | Kfhxbn | $13.2 Bil | |||
| Incyte Corp
INCY
| Fxyhbsz | Xslcbv | $13.0 Bil |
United States